Biopharma Business

Tag "Merck & Co"

FDA accepts regulatory submission for Lynparza in metastatic breast cancer

    FDA accepts regulatory submission for Lynparza in metastatic breast cancer

Lynparza has the potential to offer a new treatment option for patients with metastatic breast cancer. AstraZeneca and Merck & Co., have announced that the US Food and Drug Administration

Read Full Article

Merck pulls plug on late-stage Alzheimer’s trial

Merck & Co has terminated a Phase II/III trial testing its investigational medicine verubecestat in patients with mild to moderate Alzheimer’s disease. The move came after an external data monitoring

Read Full Article

Upcoming Events

[eventlist]

The Magazine

New Subscriber

Subscribe Here



Advertisements